BR112012012862A2 - composição farmacêutica compreendendo oligopeptídeos - Google Patents

composição farmacêutica compreendendo oligopeptídeos

Info

Publication number
BR112012012862A2
BR112012012862A2 BR112012012862A BR112012012862A BR112012012862A2 BR 112012012862 A2 BR112012012862 A2 BR 112012012862A2 BR 112012012862 A BR112012012862 A BR 112012012862A BR 112012012862 A BR112012012862 A BR 112012012862A BR 112012012862 A2 BR112012012862 A2 BR 112012012862A2
Authority
BR
Brazil
Prior art keywords
oligopeptides
pharmaceutical composition
lipophilic
composition
compounds
Prior art date
Application number
BR112012012862A
Other languages
English (en)
Inventor
Marcus Eber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44145957&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012012862(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112012012862A2 publication Critical patent/BR112012012862A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composição farmacêutica compreendendo oligopeptídeos. a presente invenção refere-se a uma composição farmacêutica de oligopeptídeos , preferivelmente oligopeptídeos cíclicos, a referida composição compreendendo um ou mais compostos lipofílicos e/ou anfifílicos, na presença ou ausência de água como os ingredientes principais, o uso dos compostos lipofílicos e/ou anfifílicos para a fabricação das composições farmacêuticas dos referidos oligopeptídeos, e métodos de fabricação de da referida composição farmacêutica.
BR112012012862A 2009-12-10 2010-12-06 composição farmacêutica compreendendo oligopeptídeos BR112012012862A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28531309P 2009-12-10 2009-12-10
US41662810P 2010-11-23 2010-11-23
PCT/EP2010/007396 WO2011069629A2 (en) 2009-12-10 2010-12-06 Pharmaceutical composition comprising oligopeptides

Publications (1)

Publication Number Publication Date
BR112012012862A2 true BR112012012862A2 (pt) 2016-08-16

Family

ID=44145957

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012862A BR112012012862A2 (pt) 2009-12-10 2010-12-06 composição farmacêutica compreendendo oligopeptídeos

Country Status (19)

Country Link
US (1) US9433577B2 (pt)
EP (1) EP2509583B1 (pt)
JP (1) JP5946770B2 (pt)
KR (1) KR20120104316A (pt)
CN (1) CN102652015B (pt)
AU (1) AU2010330364B2 (pt)
BR (1) BR112012012862A2 (pt)
CA (1) CA2783732A1 (pt)
CL (1) CL2012001310A1 (pt)
EA (1) EA022700B1 (pt)
EC (1) ECSP12012031A (pt)
ES (1) ES2742263T3 (pt)
IL (1) IL220097A (pt)
MX (1) MX2012006450A (pt)
NZ (1) NZ601109A (pt)
PE (1) PE20121359A1 (pt)
SG (1) SG181487A1 (pt)
WO (1) WO2011069629A2 (pt)
ZA (1) ZA201205103B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586545B2 (en) * 2009-05-20 2013-11-19 Merck Patent Gmbh Solid materials of {[(2S, 5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acid} and methods for obtaining them
EP3023788B1 (en) 2010-05-14 2020-02-12 The General Hospital Corporation Compositions of tumor specific neoantigens for use in treating tumours
CA2838573A1 (en) * 2011-06-09 2012-12-13 Simon Goodman Treatment of cancers and metastases with suspensions of cilengitide in carrier
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
EP3757211A1 (en) 2014-12-19 2020-12-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
MY190974A (en) 2015-05-20 2022-05-25 Massachusetts Gen Hospital Shared neoantigens
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
PL3474820T3 (pl) 2017-08-24 2024-05-13 Novo Nordisk A/S Kompozycje glp-1 i ich zastosowania
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
CA3165359A1 (en) 2020-02-18 2021-07-22 Dorthe Kot Engelund Glp-1 compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2108266C (en) * 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
AU667483B2 (en) * 1991-07-26 1996-03-28 Smithkline Beecham Corporation W/O microemulsions
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
AU719085B2 (en) * 1996-08-22 2000-05-04 Rtp Pharma Corporation Processes of preparing or stabilising microparticles
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
UA71608C2 (en) 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
MY145753A (en) * 2001-10-19 2012-03-30 Isotechnika Inc Novel cyclosporin analog formulations
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
MXPA05012467A (es) 2003-05-19 2006-02-22 Baxter Int Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
US7749485B2 (en) * 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
WO2009040071A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20110027209A1 (en) * 2008-04-08 2011-02-03 Merck Patent Gesellschaft Compositions Containing Cyclic Peptides And Methods Of Use
US8586545B2 (en) * 2009-05-20 2013-11-19 Merck Patent Gmbh Solid materials of {[(2S, 5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acid} and methods for obtaining them

Also Published As

Publication number Publication date
JP2013513556A (ja) 2013-04-22
ECSP12012031A (es) 2012-08-31
AU2010330364A1 (en) 2012-07-26
MX2012006450A (es) 2012-06-28
CN102652015A (zh) 2012-08-29
CL2012001310A1 (es) 2012-10-12
WO2011069629A2 (en) 2011-06-16
ES2742263T3 (es) 2020-02-13
ZA201205103B (en) 2013-03-27
US9433577B2 (en) 2016-09-06
US20120288539A1 (en) 2012-11-15
NZ601109A (en) 2014-06-27
PE20121359A1 (es) 2012-10-15
EP2509583A2 (en) 2012-10-17
JP5946770B2 (ja) 2016-07-06
EA022700B1 (ru) 2016-02-29
AU2010330364B2 (en) 2016-05-19
SG181487A1 (en) 2012-07-30
CA2783732A1 (en) 2011-06-16
IL220097A (en) 2017-03-30
WO2011069629A3 (en) 2012-03-15
KR20120104316A (ko) 2012-09-20
EA201200850A1 (ru) 2013-01-30
EP2509583B1 (en) 2019-05-15
CN102652015B (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
BR112012012862A2 (pt) composição farmacêutica compreendendo oligopeptídeos
BR112014010290B8 (pt) Composição farmacêutica na forma de dispersão sólida de ativos específicos em polímeros específicos e uso da composição farmacêutica
GT201400111A (es) Triazolopiridinas sustituidas
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
NI201400032A (es) Piridopirazinas anticancerígenas via la
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
GT201400043A (es) Imidazopiridazinas sustituidas con amino
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
CO6720961A2 (es) Imidazopiridazinas sustituidas
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
UY31922A (es) Compuestos
BR112012024673A2 (pt) composição anestésica termogelificante
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
TR200806298A2 (tr) Farmasötik formülasyon
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112013024824A2 (pt) ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
BR112012032882A2 (pt) liberação aumentada de ingredientes lopofílicos de goma de mascar com hidrocoloides
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]